Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study

Kohli, Payal; Wallentin, Lars; Reyes, Eric; Horrow, Jay; Husted, Steen; Angiolillo, Dominick; Ardissino, Diego; Maurer, Gerald; Morais, Joao; Nicolau, Jose; Oto, Ali; Storey, Robert; James, Stefan; Cannon, Christopher

doi:10.1161/circulationaha.112.124248

Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study

Kohli P., Wallentin L., Reyes E., Horrow J., Husted S., Angiolillo D. J., ...Daha Fazla

CIRCULATION, cilt.127, sa.6, ss.673-681, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 127 Sayı: 6
Basım Tarihi: 2013
Doi Numarası: 10.1161/circulationaha.112.124248
Dergi Adı: CIRCULATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.673-681
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

Background-We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (eg, cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events.